Skip to main content
Top
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology 6/2014

01-06-2014 | Retinal Disorders

Pars plana vitrectomy for treatment of advanced Coats’ disease—presentation of a modified surgical technique and long-term follow-up

Authors: Daniela Suesskind, Elke Altpeter, Merle Schrader, Karl U. Bartz-Schmidt, Sabine Aisenbrey

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 6/2014

Login to get access

Abstract

Background

To present a modified surgical technique in the treatment of retinal detachment secondary to advanced Coats’ disease in children, and report on long-term anatomical and functional outcome.

Methods

We analysed an interventional case series of 13 patients (13 eyes) with advanced Coats’ disease characterised by retinal detachment in addition to massive subretinal exudates and vascular malformation. The presented patients underwent pars plana vitrectomy (PPV), including a modified technique of exocryotherapy applied after fluid–air exchange in order to achieve complete treatment of the vascular changes, to reduce associated side-effects, and to avoid retinectomy and silicone oil tamponade.

Results

Within a median follow-up period of 37 months (range: 18–66 months), no enucleation was necessary. Four eyes (31 %) did not need any further therapy, and in nine eyes (69 %) additional treatments were performed. Six patients (46 %) required revisional surgery with silicone oil tamponade. In ten eyes (77 %), the pathologic vessels and exudates finally regressed and the retina reattached. Visual acuity (VA) could be stabilized in the majority of patients: in three eyes (27 %) VA improved, in four eyes (36 %) VA remained stable, in four eyes (36 %) visual acuity (VA) deteriorated, and in two eyes VA could not be evaluated.

Conclusions

The presented modified technique allows for sufficient cryotherapy of vascular malformations, even in the presence of massive exudation, in a subset of patients with advanced Coats’ disease, and thus may reduce surgery-related complications and improve the rehabilitation process of these young patients.
Literature
1.
go back to reference Coats G (1908) Forms of retinal diseases with massive exudation. R Lond Ophthalmol Hosp Rep 17:440–525 Coats G (1908) Forms of retinal diseases with massive exudation. R Lond Ophthalmol Hosp Rep 17:440–525
2.
go back to reference Shields JA, Shields CL, Honovar SG, Demirci H (2001) Clinical variations and complications of Coats disease in 150 cases: the 2000 Sanford Gifford memorial lecture. Am J Ophthalmol 131:561–571PubMedCrossRef Shields JA, Shields CL, Honovar SG, Demirci H (2001) Clinical variations and complications of Coats disease in 150 cases: the 2000 Sanford Gifford memorial lecture. Am J Ophthalmol 131:561–571PubMedCrossRef
3.
go back to reference Silodor SW, Augsburger JJ, Shields JA, Tasman W (1988) Natural history and management of advanced Coats’ disease. Ophthalmic Surg 19:89–93PubMed Silodor SW, Augsburger JJ, Shields JA, Tasman W (1988) Natural history and management of advanced Coats’ disease. Ophthalmic Surg 19:89–93PubMed
4.
go back to reference Shields JA, Shields CL, Honovar SG, Demirci H, Cater J (2000) Classification and management of Coats’ disease: the 2000 Proctor Lecture. Am J Ophthalmol 131:572–583CrossRef Shields JA, Shields CL, Honovar SG, Demirci H, Cater J (2000) Classification and management of Coats’ disease: the 2000 Proctor Lecture. Am J Ophthalmol 131:572–583CrossRef
5.
go back to reference Shields JA, Shields CL (2001) Review: Coats disease. The 2001 LuEsther T. Mertz lecture. Retina 22:80–91CrossRef Shields JA, Shields CL (2001) Review: Coats disease. The 2001 LuEsther T. Mertz lecture. Retina 22:80–91CrossRef
6.
go back to reference Krause L, Kreusel K-M, Jandeck C, Kellner U, Foerster MH (2001) Vitrektomie bei fortgeschrittenem Morbus Coats. Ophthalmologe 98:387–390PubMedCrossRef Krause L, Kreusel K-M, Jandeck C, Kellner U, Foerster MH (2001) Vitrektomie bei fortgeschrittenem Morbus Coats. Ophthalmologe 98:387–390PubMedCrossRef
7.
go back to reference Kranias G, Krebs TP (2002) Advanced Coats’ disease successfully managed with vitreo-retinal surgery. Eye 16:500–501PubMedCrossRef Kranias G, Krebs TP (2002) Advanced Coats’ disease successfully managed with vitreo-retinal surgery. Eye 16:500–501PubMedCrossRef
9.
go back to reference Mrejen S, Metge F, Denion E, Dureau P, Edelson C, Capuot G (2008) Management of retinal detachment in Coats' disease. Study of 15 cases. Retina 28:S26–S32PubMedCrossRef Mrejen S, Metge F, Denion E, Dureau P, Edelson C, Capuot G (2008) Management of retinal detachment in Coats' disease. Study of 15 cases. Retina 28:S26–S32PubMedCrossRef
10.
go back to reference Yoshizumi MO, Kreiger AE, Lewis H, Foxman B, Hakakha B (1995) Vitrectomy techniques in late-stage Coats'-like exudative retinal detachment. Doc Ophthalmol 90:387–394PubMedCrossRef Yoshizumi MO, Kreiger AE, Lewis H, Foxman B, Hakakha B (1995) Vitrectomy techniques in late-stage Coats'-like exudative retinal detachment. Doc Ophthalmol 90:387–394PubMedCrossRef
11.
go back to reference Sterigiou PK, Symeonidis C, Dimitrakos SA (2009) Coats’ disease: treatment with intravitreal bevacizumab and laser photocoagulation. Acta Ophthalmol (Copenh) 87:687–688CrossRef Sterigiou PK, Symeonidis C, Dimitrakos SA (2009) Coats’ disease: treatment with intravitreal bevacizumab and laser photocoagulation. Acta Ophthalmol (Copenh) 87:687–688CrossRef
12.
go back to reference Cackett P, Wong D, Cheung CMG (2010) Combined intravitreal bevacizumab and argon laser treatment for Coats’ disease. Acta Ophthalmol (Copenh) 88:e48–e49CrossRef Cackett P, Wong D, Cheung CMG (2010) Combined intravitreal bevacizumab and argon laser treatment for Coats’ disease. Acta Ophthalmol (Copenh) 88:e48–e49CrossRef
13.
go back to reference Entezari, Ramezani A, Safavizadeh L, Bassimia N (2010) Resolution of macular edema in Coats’ disease with intravitreal bevacizumab. Indian J Ophthalmol 58:80–82PubMedCentralPubMedCrossRef Entezari, Ramezani A, Safavizadeh L, Bassimia N (2010) Resolution of macular edema in Coats’ disease with intravitreal bevacizumab. Indian J Ophthalmol 58:80–82PubMedCentralPubMedCrossRef
14.
go back to reference Kaul S, Uparkar M, Mody K, Walinjkar J, Kothari M, Natarajan S (2010) Intravitreal anti-vascular endothelial growth factor agents as an adjunct in the management of Coats’ disease in children. Indian J Ophthalmol 58:76–78PubMedCentralPubMedCrossRef Kaul S, Uparkar M, Mody K, Walinjkar J, Kothari M, Natarajan S (2010) Intravitreal anti-vascular endothelial growth factor agents as an adjunct in the management of Coats’ disease in children. Indian J Ophthalmol 58:76–78PubMedCentralPubMedCrossRef
15.
go back to reference Böhm MRR, Uhlig CE (2011) Use of intravitreal triamcinolone and bevacizumab in Coats’ disease with central macular edema. Graefes Arch Clin Exp Ophthalmol 249:1099–1101PubMedCrossRef Böhm MRR, Uhlig CE (2011) Use of intravitreal triamcinolone and bevacizumab in Coats’ disease with central macular edema. Graefes Arch Clin Exp Ophthalmol 249:1099–1101PubMedCrossRef
16.
go back to reference Zhao T, Wang K, Ma Y, Jiang Y-R (2011) Resolution of total retinal detachment in Coats’ disease with intravitreal injection of bevacizumab. Graefes Arch Clin Exp Ophthalmol 249:1745–1746PubMedCrossRef Zhao T, Wang K, Ma Y, Jiang Y-R (2011) Resolution of total retinal detachment in Coats’ disease with intravitreal injection of bevacizumab. Graefes Arch Clin Exp Ophthalmol 249:1745–1746PubMedCrossRef
17.
go back to reference Ghazi NG, Al Shamsi H, Larsson J, Abboud E (2012) Intravitreal triamcinolone in Coats’ disease. Ophthalmology 119:648–649PubMedCrossRef Ghazi NG, Al Shamsi H, Larsson J, Abboud E (2012) Intravitreal triamcinolone in Coats’ disease. Ophthalmology 119:648–649PubMedCrossRef
18.
go back to reference Zheng X-X, Jiang Y-R (2013) The effect of intravitreal bevacizumab injection as the initial treatment for Coats’ disease. Graefes Arch Clin Exp Ophthalmol Jul 20 [Epub ahead of print]. doi:10.1007/s00417-013-2409-1 Zheng X-X, Jiang Y-R (2013) The effect of intravitreal bevacizumab injection as the initial treatment for Coats’ disease. Graefes Arch Clin Exp Ophthalmol Jul 20 [Epub ahead of print]. doi:10.​1007/​s00417-013-2409-1
19.
go back to reference Ray R, Barañano DE, Hubbard GB (2013) Treatment of Coats’ disease with intravitreal bevacizumab. Br J Ophthalmol 97:272–277PubMedCrossRef Ray R, Barañano DE, Hubbard GB (2013) Treatment of Coats’ disease with intravitreal bevacizumab. Br J Ophthalmol 97:272–277PubMedCrossRef
20.
go back to reference Shields JA, Shields CL (2001) Differentiation of Coats’ disease and retinoblastoma. J Pediatr Ophthalmol Strabismus 38:262–266PubMed Shields JA, Shields CL (2001) Differentiation of Coats’ disease and retinoblastoma. J Pediatr Ophthalmol Strabismus 38:262–266PubMed
21.
go back to reference Shields CL, Schoenberg E, Kocher K, Shukla SY, Kaliki S, Shields JA (2013) Lesions simulating retinoblastoma (pseudoretinoblastoma) in 604 cases. Results based on age at presentation. Ophthalmology 120:311–316PubMedCrossRef Shields CL, Schoenberg E, Kocher K, Shukla SY, Kaliki S, Shields JA (2013) Lesions simulating retinoblastoma (pseudoretinoblastoma) in 604 cases. Results based on age at presentation. Ophthalmology 120:311–316PubMedCrossRef
22.
go back to reference Nagasaki H, Shinagawa K, Mochizuki M (1998) Risk factors for proliferative vitreoretinopathy. Prog Retin Eye Res 17:77–98PubMedCrossRef Nagasaki H, Shinagawa K, Mochizuki M (1998) Risk factors for proliferative vitreoretinopathy. Prog Retin Eye Res 17:77–98PubMedCrossRef
23.
go back to reference Singh AK, Michels RG, Glaser BM (1986) Scleral indentation following cryotherapy and repeat cryotherapy enhance release of viable retinal epithelial cells. Retina 6:176–178PubMed Singh AK, Michels RG, Glaser BM (1986) Scleral indentation following cryotherapy and repeat cryotherapy enhance release of viable retinal epithelial cells. Retina 6:176–178PubMed
24.
go back to reference Lee JH, Kim SJ, Chung H (1995) The effect of subtenon injection of methylprednisolone acetate on the breakdown of blood retinal barrier after cryotherapy. Korean J Ophthalmol 9:1–6PubMed Lee JH, Kim SJ, Chung H (1995) The effect of subtenon injection of methylprednisolone acetate on the breakdown of blood retinal barrier after cryotherapy. Korean J Ophthalmol 9:1–6PubMed
25.
go back to reference Theodossiadis GP (1974) Some clinical, fluorescein-angiographic, and therapeutic aspects of Coats’ disease. J Pediatr Ophthalmol Strabismus 16:257–262 Theodossiadis GP (1974) Some clinical, fluorescein-angiographic, and therapeutic aspects of Coats’ disease. J Pediatr Ophthalmol Strabismus 16:257–262
26.
go back to reference Shapiro MJ, Show CC, Karth PA, Kiernan DF, Blair MP (2011) Effects of green diode laser in the treatment of pediatric Coats' disease. Am J Ophthalmol 151:725–731PubMedCrossRef Shapiro MJ, Show CC, Karth PA, Kiernan DF, Blair MP (2011) Effects of green diode laser in the treatment of pediatric Coats' disease. Am J Ophthalmol 151:725–731PubMedCrossRef
27.
go back to reference Schefler AC, Berrocal A, Murray T (2008) Advanced Coats’ disease. Management with repetitive aggressive laser ablation therapy. Retina 28:S38–S41PubMedCrossRef Schefler AC, Berrocal A, Murray T (2008) Advanced Coats’ disease. Management with repetitive aggressive laser ablation therapy. Retina 28:S38–S41PubMedCrossRef
28.
go back to reference Kirath H, Eldem B (1998) Management of moderate to advanced Coats’ disease. Ophthalmologica 212:19–22CrossRef Kirath H, Eldem B (1998) Management of moderate to advanced Coats’ disease. Ophthalmologica 212:19–22CrossRef
29.
go back to reference Mulvihill A, Morris B (2010) A population-based study of Coats' disease in the United Kingdom II: investigation, treatment, and outcomes. Eye 24:1802–1807PubMedCrossRef Mulvihill A, Morris B (2010) A population-based study of Coats' disease in the United Kingdom II: investigation, treatment, and outcomes. Eye 24:1802–1807PubMedCrossRef
30.
go back to reference Ramasubramanian A, Shields CL (2012) Bevacizumab for Coats’ disease with exudative retinal detachment and risk of vitreoretinal traction. Br J Ophthalmol 96:356–359PubMedCrossRef Ramasubramanian A, Shields CL (2012) Bevacizumab for Coats’ disease with exudative retinal detachment and risk of vitreoretinal traction. Br J Ophthalmol 96:356–359PubMedCrossRef
Metadata
Title
Pars plana vitrectomy for treatment of advanced Coats’ disease—presentation of a modified surgical technique and long-term follow-up
Authors
Daniela Suesskind
Elke Altpeter
Merle Schrader
Karl U. Bartz-Schmidt
Sabine Aisenbrey
Publication date
01-06-2014
Publisher
Springer Berlin Heidelberg
Published in
Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 6/2014
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-013-2512-3

Other articles of this Issue 6/2014

Graefe's Archive for Clinical and Experimental Ophthalmology 6/2014 Go to the issue